It seems NSCLC is proving a somewhat thornier beast than the majors had perhaps anticipated.
If OS is the main game and Merck does want to roll Pembro/CVA-21 combo into something more substantial in NSCLC because of their superior OS experiences, I would like to think VLA will squeeze their goolies so they cough up for the right to play together.
Show me the money.
- Forums
- ASX - By Stock
- VLA
- Keytruda and Merck article about problems with lung cancer trial.
Keytruda and Merck article about problems with lung cancer trial., page-5
Featured News
Add VLA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online